How Merck's $1B AI Wager Could Reshape Drug Development

Merck commits up to $1B to deploy Google Cloud's Gemini AI across its entire global pharma operation

29 Apr 2026

Merck is not dipping a toe into artificial intelligence. The pharmaceutical giant announced a multi-year deal with Google Cloud worth up to $1 billion on April 22, one of the largest AI infrastructure commitments in the industry's history, and it covers far more than a single department or use case.

The partnership deploys Google Cloud's Gemini Enterprise platform across every corner of Merck's operation: drug research and development, manufacturing, commercial functions, and corporate infrastructure. That breadth matters. Most pharma-AI partnerships unveiled in recent years have targeted a narrow slice of the pipeline, molecule design here, clinical trial optimization there. This one is end-to-end.

Google Cloud engineers will embed directly with Merck's teams to build and roll out the technology, bringing all 75,000 of the company's global employees into an AI-enabled operating model. The plan centers on intelligent agents, software capable of carrying out complex, multi-step tasks with minimal human input, to accelerate both scientific output and manufacturing efficiency at scale.

The timing is notable. Novo Nordisk revealed a partnership with OpenAI just days earlier, and AWS launched its own drug discovery platform the same week. But analysts widely view the Merck-Google deal as the most sweeping yet, extending well beyond the lab and into the business operations that keep a global pharmaceutical company running.

Merck, which reported revenues of roughly $65 billion in 2025, says it will retain full ownership of its data within privacy-compliant, governed environments. That assurance is deliberate. Cybersecurity experts have raised concerns about giving AI agents broad access across critical business workflows before robust oversight frameworks are in place.

The commercial logic is hard to argue with. Bringing a single medicine to market can take more than a decade and cost north of $2 billion. Platforms that compress those timelines, even modestly, carry enormous value. With major technology providers now embedded inside the world's largest pharmaceutical companies, AI-native drug development is not on the horizon. It is already underway.